Skip to main content
Conference Coverage

Coverage Withdrawal Associated With Worse Health Outcomes Among Patients With Obesity

Key Takeaways:

  • A survey of 209 patients with obesity found that losing coverage for glucagon-like peptide-1 receptor agonists (GLP-1 RAs) resulted in disease progression, with over half of the participants reporting at least 1 new or worsening obesity-related complication.
  • Disease severity and weight recurrence were associated with worse health outcomes, indicating a vulnerable patient population who may benefit most from disease management.
  • Patients with higher household incomes had fewer reports of obesity-related complications, most likely because they could afford to maintain treatment adherence after losing coverage.

A poster presented at ObesityWeek 2026 examined the health outcomes associated with GLP-1 RA coverage withdrawal experienced by patients with obesity.

Study Methods and Outcomes

Researchers conducted a survey of patients with obesity who participated in an academic obesity medicine program between 2023 and 2025 who had lost GLP-1 RA coverage 20 months prior to completing the survey.

The primary outcome was reports of new or worsening obesity-related complications among participants, including cardiometabolic, hepatic, gastrointestinal, sleep, reproductive, and musculoskeletal conditions.

Lost Coverage Associated With Treatment Discontinuation and Disease Progression

The survey included 209 participants, 57.4% of whom reported at least 1 new or worsening obesity-related complication after losing GLP-1 RA coverage, and 32.5% reported 2 or more.

Only 20 participants (9.6%) maintained a healthy body mass index (BMI), most likely due to a majority remaining on obesity treatments after coverage withdrawal. Conversely, less than half (45.2%) of patients with overweight or obesity adhered to GLP-1 RA therapy.

Patients with higher classes of obesity (class 2 and 3) were more likely to experience new or worsening symptoms compared to those in lower disease classes, illustrating the negative impact of disease severity. In addition, rates of new or worsening symptoms were also higher among participants with 10% or greater weight reoccurrence compared to those with less than 10% recurrence.

Participants with a household income of $100 000 or higher and those who maintained GLP-1 RA therapy were less likely to report new or worsening complications after coverage withdrawal. This finding shows how income is associated with adherence, since treatments were primarily paid out of pocket.

In addition to poorer health outcomes, lost GLP-1 RA coverage was associated with lower work productivity, with many participants reporting increases in work absences due to disease complications.

Implications for Managed Care

GLP-1 RAs are effective but costly obesity treatments, making coverage and treatment adherence challenging for payers and patients.

These findings illustrate the health and productivity complications associated with GLP-1 RA coverage withdrawal among patients with obesity.

Many participants reported treatment discontinuation after losing coverage, with only a select few able to continue therapy by paying for medications out of pocket.

Healthy BMI, higher household income, and treatment adherence were associated with better disease control. On the other hand, patients with higher disease severity and weight recurrence were more likely to experience new or worsening obesity-related complications.

Reference

Francis J, Ernest D, Jang S, et al. Health consequences following employer withdrawal of GLP-1 receptor agonist coverage for obesity. Poster 630. Abstract presented at: ObesityWeek 2026; November 14-17, 2026; Washington, DC.